Signature Wealth Management Partners LLC Has $224,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Signature Wealth Management Partners LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,729 shares of the biopharmaceutical company’s stock after selling 768 shares during the quarter. Signature Wealth Management Partners LLC’s holdings in Pfizer were worth $224,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Olistico Wealth LLC bought a new position in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer during the second quarter worth about $29,000. Quarry LP acquired a new stake in Pfizer during the second quarter valued at approximately $31,000. Financial Connections Group Inc. bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $34,000. Finally, ESL Trust Services LLC bought a new position in shares of Pfizer during the 1st quarter worth approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Trading Up 1.5 %

NYSE PFE opened at $28.87 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $163.60 billion, a PE ratio of -62.76, a P/E/G ratio of 0.99 and a beta of 0.67. The stock has a 50-day simple moving average of $29.08 and a 200 day simple moving average of $28.54. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the business posted $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.